Srinivas Teppala
Dr. Sri Teppala is a postdoctoral researcher at the Kolling Institute, University of Sydney and Northern Sydney Local Health District. He has a background in Clinical Medicine, Epidemiology and Health Economics. Current research includes several projects on the value for money of pharmacogenomic and genetic testing-guided treatments in human cancer. Previous work includes the economics of germline genetic testing in prostate cancer, the epidemiology of novel biomarkers in cardiovascular disease, diabetes, metabolic syndrome, chronic kidney disease and sleep disorders. Dr. Teppala has also performed Health Technology Assessment (HTA) for the Medical Services Advisory Committee (MSAC) and the Pharmaceutical Benefits Advisory Committee (PBAC), Australia.
Abstracts this author is presenting:
